Biopharmaceuticals & Therapies
BioPharma is not only about molecule development: it is the ability to turn a biological hypothesis into a treatment that withstands CMC, clinical studies, regulatory scrutiny and real-world practice. At Technoscience, we read biopharmaceuticals and innovative therapies along a complete trajectory: from proof of concept to TRL7, from the EMA/FDA pathway to models for rare diseases, with the objective of avoiding premature enthusiasm and costly delays. This section describes how we work on pipelines, regulatory pathways and studies in areas of high clinical complexity.
An axis connecting laboratory, regulatory and market
In this section you will find three pathways that make the area concrete Biopharmaceuticals & Therapies. These are not general-audience articles, but working maps designed for those who must turn a biological hypothesis into a credible, sustainable development programme aligned with CMC, clinical studies and the regulatory pathway.
Biopharmaceutical Pipelines: From Proof of Concept to TRL 7 shows how to build a pipeline that does not stall at the first scale-up step: from a PoC that genuinely matters, to CMC that holds up as you grow, through to milestones and KPIs that guide decisions across Phases 1, 2 and 3. Innovative Therapies and Regulatory Pathways (EMA/FDA) goes into the substance of procedures, accelerated pathways and dossiers: how to prepare scientific advice, when to request Orphan/PRIME/Fast Track/Breakthrough, and what “data quality” genuinely means to a regulator. Rare-Disease Studies: Models, Endpoints and Clinical Sustainability addresses the most delicate territory: natural history, registries, adaptive designs, external controls, PROs and sustainability beyond the p-value.
If you work in BioPharma development, clinical practice, regulatory affairs, CMC or investment in innovative therapies, each of these pathways is designed to give you operational criteria, not slogans, and to show you how Technoscience can contribute to the project from the first proof of concept through to TRL7 and beyond.
How to work with us: what is really needed at the outset
To assess a project in the Biopharmaceuticals & Therapies we ask for a number of concrete elements. First: a clear biological hypothesis and a defined clinical question, not a generic scope. Second: the state of the CMC and studies, together with what has already been done (preclinical, Phase 1/2, registries, available data) and the main perceived risks. Third: the realistic regulatory context, including possible accelerated pathways (Orphan, PRIME, Fast Track, Breakthrough) and foreseeable obstacles. In return, we offer a due diligence on the pipeline, a credible proposed TRL pathway and, where appropriate, coordination between clinicians, CMC, regulatory and investors to avoid wasting time and resources.
Choose Technoscience!
If you are developing a biopharmaceutical or an innovative therapy, request a fit check: in a short call, we align the biological hypothesis, CMC status, study design and progress, and regulatory risks and opportunities. If the scope is sound, we jointly plan a pathway from proof-of-concept to TRL7, with clear milestones, decision gates and a realistic EMA/FDA strategy. If essential elements are still missing, we say so immediately, so you avoid spending time and budget on a fragile trajectory.
Frequently Asked Questions
The questions you ask us most often
It is an approach that defines the the actual biology of the disease (tissues, markers and omics profiles where indicated) and links it to diagnostic and therapeutic decisions diagnostic and therapeutic personalised. It does not stop at generic classifications or guidelines applied wholesale: it builds a individual pathway measurable through robust clinical endpoints.
We start from risk classification and by the clinical scope of use. Requirements, risk management, clinical evaluation, software validation where present, and a plan for post-market surveillance. Documentation accompanies the entire lifecycle; compliance is not an event, it is a process.
It means speaking the standard languages of the sector (e.g. HL7/FHIR), maintain stable mappings, guarantee import/export without lock-in, and allow clinicians to see the data within its context (EHR, LIS, PACS) without duplication or manual copying.
Data-driven platforms collect, normalise and interpret medical data from certified devices, turning raw signals into clinically useful information for prevention, diagnosis and continuous monitoring.
Certified medical devices such as portable ECGs, pulse oximeters, multisensor wearables and environmental sensors underpin reliable remote monitoring and proactive prevention, both in healthcare and in the workplace.
Informed consent specific and understandable, compliant data governance, measures for pseudonymisation/de-identification, safety plans and audit documented, controls on the pre-analytical and analytical phases, and a return-of-results plan of results where required. If the project leads to clinical decisions or regulated products, additional requirements apply (clinical evaluations, MDR, GCP), and must be integrated from the outset.
An enabling role. The biobanks ensure traceable and comparable samples; the omics broaden the understanding of the underlying mechanisms (inflammatory, metabolic and genetic). When integrated with rigorous protocols and real-world data, make reproducible the evidence and accelerate translation towards clinical trials or clinical adoption.
With privacy by design and security by design: data minimisation, encryption in transit and at rest, access control, environment segmentation, audit trails and incident-response procedures. Roles and legal bases are made explicit; suppliers are also assessed for business continuity.
Integrated platforms enable intelligent surveillance, anticipating clinical events through composite indices and predictive algorithms and facilitating timely, personalised interventions instead of fixed-interval checks.
The data collected undergo normalisation, quality verification and audit-trail processes; they are managed according to security and privacy protocols compliant with applicable regulations (such as the GDPR).
With a reasoned request that describes purposes, study design, ethical criteria and sample/data requirements. The competent committee assesses consistency, proportionality and impact. Access, when granted, is conditional with quality protocols, traceability of use and the return of outcomes needed to update the biobank’s knowledge base.